Unique Findings With Binimetinib Plus Imatinib in Advanced GIST
Ping Chi, MD, a medical oncologist, and Geoffrey Beene Junior Faculty chair at Memorial Sloan Kettering Cancer Center, reviews the results of a phase 2 study of binimetinib plus imatinib as treatment of patients with untreated advanced gastrointestinal stromal tumors.
Ping Chi, MD, a medical oncologist, and Geoffrey Beene Junior Faculty chair at Memorial Sloan Kettering Cancer Center, reviews the results of a phase 2 study of binimetinib (Mektovi) plus imatinib (Gleevec) as treatment of patients with untreated advanced gastrointestinal stromal tumors.
Ping says that on top of achieving the primary end point of objective response, the select subgroup of patients was able to undergo resection. There were 7 patients who were considered unresectable at baseline, and 6 of them were resectable after treatment with the combination.
It was also notable in the study that the pathological responses in patients were deeper compared to the traditional RECIST responses, Ping explains. Looking ahead, she believes responses should be evaluated beyond.
Ilson Examines Chemoimmunotherapy Regimens for Metastatic Gastroesophageal Cancers
December 20th 2024During a Case-Based Roundtable® event, David H. Ilson, MD, PhD, discussed the outcomes of the CheckMate 649, CheckMate 648, and KEYNOTE-859 trials of chemoimmunotherapy regimens in patients with upper GI cancers.
Read More
Tumor Treating Fields Show Significant Survival Benefit in Pancreatic Cancer
December 2nd 2024The PANOVA-3 trial demonstrated a significant 2-month overall survival improvement when adding tumor treating fields to gemcitabine and nab-paclitaxel for patients with locally advanced pancreatic adenocarcinoma.
Read More
